Evidence map›Paper›PMID 42340391›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Beyond tumor tracing: physiological uptake of sympathetic ganglia on somatostatin receptor PET/CT - prevalence, patterns, and biological rationale.

Meixi Liu, Ruping Hong, Yuwei Zhang, Xinchun Yan, Jingnan Wang, Haiqiong Zhang, Chao Ren, Zhenghai Huang, Jing Shi, Yuejuan Cheng and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meixi Liu *Department of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Ruping Hong *Department of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Yuwei Zhang *Department of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Xinchun YanDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Jingnan WangDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Haiqiong ZhangDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Chao RenDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Zhenghai HuangTheranostics and Translational Research Center, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing ShiDepartment of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Yuejuan ChengDepartment of Oncology, Peking Union Medical College Hospital, Beijing, 100730, China.
Anli TongDepartment of Endocrinology, Peking Union Medical College Hospital, Beijing, 100730, China.
Hongli JingDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Wenjia ZhuDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. zhuwenjia_pumc@163.com.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. huoli@pumch.cn.ORCID http://orcid.org/0000-0003-1216-083X

Funding

Beijing Natural Science Foundation L242062Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2025-I2M-XHCL-004, CIFMS-2023-I2M-2-002, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003, CIFMS-2021-I2M-1-025National High Level Hospital Clinical Research Funding 2022-PUMCH-D-001, 2022-PUMCH-D-002National Key R&D Program of China 2024YFC2419400, 2024YFC2419401National Natural Science Foundation of China U24A20758, 82071967Peking Union Medical College Hospital Talent Cultivation Program (Category D) UHB12582
6 · The paper itself

Abstract

purposeThis study aims to investigate the prevalence, pattern, physiological basis, and influencing factors of sympathetic ganglia uptake on [

methods[

resultsPositive sympathetic ganglia were observed in 76.2% (77/101) of patients on [

conclusionSympathetic ganglia uptake on SSTR PET/CT is a common physiological finding, featured by symmetric distribution and faint uptake. Histopathology confirming SSTR2-positive ganglionic neurons provides the biological basis for this uptake.

Indexed as

Ganglia, SympatheticPositron Emission Tomography Computed TomographyReceptors, SomatostatinAdultAgedAged, 80 and overBiological TransportFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesRadiopharmaceuticalsReceptors, Somatostatin[18F]AlF-NOTA-LM3NeuronPET/CTSomatostatin receptorSympathetic ganglia

Identifiers

PMID42340391

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.